

Stem and progenitor cells in preterm infants : role in the pathogenesis and potential for therapy

Citation for published version (APA):

Borghesi, A. (2015). *Stem and progenitor cells in preterm infants : role in the pathogenesis and potential for therapy*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20150128ab>

Document status and date:

Published: 01/01/2015

DOI:

[10.26481/dis.20150128ab](https://doi.org/10.26481/dis.20150128ab)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Valorisation: Biosafety of umbilical cord-derived mesenchymal stromal cells (MSCs)

The study reported in chapter 5 concerns the biosafety of stem cells, specifically MSCs isolated from the umbilical cord, to be used in cell therapy in the setting of neonatal medicine.

RELEVANCE. The umbilical cord is a promising source of MSCs, but studies on the genetic stability of umbilical cord-derived MSCs were lacking. In a historical moment in which stem cells occupy a substantial part of the medical news in the media, it seems important to accurately study the potential risks associated with a specific cell therapy.

TARGET GROUPS. MSCs are polyvalent cells with different behaviors in different environments, and could be suitable for treating a series of diseases affecting all ages, from the neonatal age to adulthood, ranging from graft versus host disease in bone marrow transplant recipients, to inflammatory bowel diseases, neuroinflammatory diseases, and diseases of the preterm infant. All the people (patients) that could benefit from therapies with MSCs may be interested in our results.

ACTIVITIES/PRODUCTS. In the context of cell factories, specialized laboratories dedicated to the production of cell products destined to clinical use, the identification of genomic imbalances through array-comparative genomic hybridization should become a routine procedure for every lot of MSCs, in order to exclude from clinical use the lots with cells carrying imbalances.

INNOVATION. Similar studies had been carried out for other stem/progenitor cell populations, but not for umbilical cord-derived MSCs. Our study adds this important information regarding a cell population isolated from the umbilical cord, a promising source given its availability and the few ethical issues related to its collection.

SCHEDULE/IMPLEMENTATION. In the setting of neonatal medicine, one experimental work suggests that umbilical cord-derived MSCs may mitigate the phe-

notype of experimental BPD. If these results will be confirmed and umbilical cord-derived MSCs will be object of a clinical trial in preterm newborn infants, routine screening for genomic imbalances of the lots to be used in trials will be performed before the cell products are administered to the patients.